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Background: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR
Gram-negative bacilli (MDR-GNB).
Objectives: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical
isolates from hospitals in southern Spain.
Methods: Two hundred and thirty-one isolates of successful clones were tested: 125 Enterobacterales (121
ESBL- and/or carbapenemase-producing Klebsiella pneumoniae and 4 carbapenemase-producing Enterobacter
cloacae), 80 Acinetobacter baumannii, 6 Pseudomonas aeruginosa and 20 Stenotrophomonas maltophilia.
Ceftolozane/tazobactam, ceftazidime, ceftazidime/avibactam, cefepime, aztreonam, meropenem, amikacin,
ciprofloxacin, colistin and tigecycline were used as comparators against Enterobacterales, P. aeruginosa and
A. baumannii. Minocycline, levofloxacin and trimethoprim/sulfamethoxazole were studied against S. maltophilia
instead of aztreonam, ciprofloxacin and cefepime. MICs were determined by broth microdilution according to
CLSI guidelines. MIC determination was performed in CAMHB for all antimicrobials except cefiderocol, where
iron-depleted CAMHB was used.
Results: Cefiderocol showed potent in vitro activity against the isolates analysed. MIC50 and MIC90 values were
in the ranges 0.125–8 mg/L and 0.5–8 mg/L, respectively, and 98% of isolates were inhibited at 4 mg/L.
Only five isolates showed cefiderocol MICs of >4 mg/L: three ST2/OXA-24/40-producing A. baumannii, one
ST114/VIM-1-producing E. cloacae and one ST114/VIM-1!OXA-48-producing E. cloacae. All KPC-3-producing
K. pneumoniae were susceptible to cefiderocol, even those resistant to ceftazidime/avibactam. P. aeruginosa iso-
lates showed cefiderocol MICs of <4 mg/L, including those resistant to ceftolozane/tazobactam. S. maltophilia
isolates displayed cefiderocol MICs of <4 mg/L, including those resistant to levofloxacin and/or trimethoprim/
sulfamethoxazole.
Conclusions: Cefiderocol showed excellent activity against MDR-GNB, including carbapenem-resistant isolates,
and was the most active antimicrobial tested against this collection.
Introduction
MDR Gram-negative bacilli (MDR-GNB) represent an important
public health problem, which was recently described by the WHO
as a global crisis.1 Nosocomial and healthcare-associated infec-
tions caused by MDR organisms significantly increase morbidity,
mortality and medical costs.2 Infections caused by these bacteria
are very difficult to treat since strains are resistant to all first-line
anti-Gram-negative antibiotics, such as b-lactams, and to fluoro-
quinolones. A few new antimicrobials such as ceftazidime/avibac-
tam and ceftolozane/tazobactam are available in many countries,
but these compounds have very limited activity against bacteria
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producing MBLs.3 Alternative drugs, such as colistin, tigecycline,
fosfomycin and aminoglycosides, are frequently the only options.3
The WHO has published a priority list of pathogens for
which the development of new antibiotics is urgently required.
Among these microorganisms are carbapenem-resistant
Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa
and carbapenem-resistant Acinetobacter baumannii.4
The spread and persistence of these pathogens is favoured by
selection for successful, high-risk (HR) clones. These clones are
characterized by their enhanced ability to cause nosocomial
outbreaks and to develop or acquire resistance to multiple antimi-
crobials, including extended-spectrum agents such as carbape-
nems. Horizontal transfer of plasmids carrying genes that encode
carbapenemases is probably one of the most important factors in
the success of these epidemic clones.5 MBL-producing GNB are
also increasing, including in Spain.6
Cefiderocol is a new parenteral catechol-substituted sidero-
phore cephalosporin. This antimicrobial has a unique mechanism
of penetration into bacterial cells. Experiments with P. aeruginosa
have shown that cefiderocol can easily enter the periplasmic
space using the iron transport system, via the binding of the cat-
echol moiety of the drug to extracellular trivalent iron.7 The
high activity of cefiderocol is also due to its increased stability
against various types of b-lactamases, including serine-based
and metallo-type carbapenemases.8 In contrast, cefiderocol
shows weak or no activity against Gram-positive and anaerobic
bacteria.9
Cefiderocol has been reported to have potent in vitro activity
against MDR-GNB, including carbapenem-resistant strains of
Enterobacterales, P. aeruginosa and A. baumannii, as well as
against Stenotrophomonas maltophilia.10–12
In vivo human pharmacokinetic and pharmacokinetics/
pharmacodynamics data from an animal infection model have
been published.13,14 Cefiderocol has demonstrated efficacy
against GNB based on human pharmacokinetic properties.14
A recent report demonstrated the efficacy and safety of cefi-
derocol as monotherapy for the treatment of invasive infections
caused by MDR A. baumannii and Klebsiella pneumoniae.15
The purpose of this study was to provide data on the compara-
tive in vitro antimicrobial activity of cefiderocol against a collection
of cephalosporin- and/or carbapenem-resistant Gram-negative HR
clones with characterized antibiotic resistance mechanisms from
clinical sources, isolated in hospitals in southern Spain.
Methods
Bacteria
The isolates of MDR-GNB tested in this study (n = 231) were selected from a
well-characterized collection held in the Reference Laboratory of the
Andalusian programme for the surveillance and control of healthcare-
associated infections and antibiotic stewardship (PIRASOA programme),
based in the Hospital Universitario Virgen Macarena, Seville, Spain.16,17 The
selected isolates came from 27 hospitals in the eight provinces of
Andalusia. Sixteen isolates from 2014 were selected, 37 from 2015, 92
from 2016, 84 from 2017 and 2 from 2018. The inclusion criteria for selec-
tion of isolates were those belonging to HR clones, except for S. maltophilia,
and MDR isolates. Isolates of Enterobacterales (n = 125; 121 K. pneumoniae
and 4 Enterobacter cloacae) were chosen if they were ESBL and/or
carbapenemase producers. Isolates of A. baumannii (n = 80) were selected
if they demonstrated oxacillinase production and P. aeruginosa (n = 6) if
they were resistant to carbapenems. Twenty isolates of S. maltophilia
were included, based solely on identification and MDR phenotype. The
characteristics and resistance determinants of selected isolates are
shown in Table 1.
Bacterial identification, identification of resistance
genes and molecular epidemiology
The identification of isolates was confirmed at the reference laboratory
using MALDI-TOF MS (MALDI-TOF Biotyper 3.1; Microflex Bruker, Madrid,
Spain).
The presence of ESBL (CTX-M group) and carbapenemases (NDM/VIM/
KPC/IMP/OXA-48 groups for Enterobacterales and P. aeruginosa, and OXA
for A. baumannii) was evaluated by PCR and DNA sequencing.18–20
PFGE analysis of XbaI- (Enterobacterales), SpeI- (P. aeruginosa) and
ApaI-digested (A. baumannii) DNA (http://www.cdc.gov/pulsenet) was
used to determine the degree of genetic relatedness between isolates.
Isolates differing by two or more bands in PFGE assays were assigned to
different pulsotypes, except for K. pneumoniae ST512 and ST258, for which
different pulsotypes were assigned when they differed in one band. A den-
drogram was created with Fingerprinting 3.0 software (Bio-Rad), using the
Dice coefficient with position tolerance settings of 1% optimization and
1.2% band position tolerance. PFGE was not performed for S. maltophilia.
The MLST scheme developed by the Institut Pasteur was used to charac-
terize a subset of isolates representing different PFGE clusters and all
S. maltophilia were included (https://bigsdb.pasteur.fr/index.html). All pul-
sotypes assigned to the same MLST were considered to belong to the same
clone. Whenever possible, isolates from the same clone with different
pulsotypes were selected.
Table 1. Isolates of MDR GNB tested (n = 231)
Species
Clone/resistance
determinant
No. of isolates
(no. of pulsotypes)
A. baumannii ST2/OXA-23 25 (17)
ST2/OXA-58 25 (14)
ST2/OXA-24/40 25 (15)
ST745/OXA-23 5 (4)
P. aeruginosa ST175 5 (NA)
ST253/IMP-16 1 (NA)
K. pneumoniae ST11/CTX-M-15 5 (5)
ST11/CTX-M-15!OXA-48 25 (9)
ST15/CTX-M-15 5 (3)
ST15/CTX-M-15!OXA-48 25 (6)
ST512/KPC-3 25 (9)
ST258/KPC-3 25 (9)
ST147/KPC-3 1 (NA)
ST147/CTX-M-15!OXA-48 2 (NA)
ST147/OXA-48 1 (NA)
ST392/CTX-M-15 3 (3)
ST392/CTX-M-15!OXA-48 4 (3)
E. cloacae ST114/CTX-M-15 2 (NA)
ST114/VIM-1 1 (NA)
ST114/OXA-48!VIM-1 1 (NA)
S. maltophilia – 20 (NA)
NA, not applicable; a dash indicates data not available.
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Drug susceptibility testing
Susceptibility testing was performed using frozen broth microdilution plates
prepared by International Health Management Associates (IHMA;
Schaumburg, IL, USA) and Shionogi & Co., Ltd. (Osaka, Japan) to determine
the MICs of cefiderocol and comparators. Broth microdilution panels
included the following ranges of antimicrobial agents (mg/L) for
Enterobacterales, P. aeruginosa and A. baumannii: cefiderocol (doubling di-
lution range tested: 0.03–64), ceftolozane/tazobactam (0.03–64), merope-
nem (0.03–64), ceftazidime (0.03–64), ceftazidime/avibactam (0.03–64),
colistin (0.5–8), aztreonam (0.5–32), amikacin (4–64), ciprofloxacin
(0.25–4), cefepime (0.5–16) and tigecycline (0.25–4). For S. maltophilia, the
activities of aztreonam, ciprofloxacin and cefepime were not tested and
the in vitro activity of minocycline (2–64), levofloxacin (1–16) and trimetho-
prim/sulfamethoxazole (0.25/4.75–16/304) were studied instead.
MICs were determined by broth microdilution in CAMHB, according to
CLSI guidelines.21,22 To evaluate the antimicrobial activity of cefiderocol,
iron-depleted (ID) CAMHB was used.23 The microdilution panels included
growth control wells for both CAMHB and ID-CAMHB. Panels were incubated
in ambient air at 35C for 16–20 h before reading MIC endpoints. In parallel,
Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as
control strains on each day of testing, checking that all quality control
results were within the specified CLSI ranges for ceftolozane/tazobactam,
meropenem, ceftazidime, ceftazidime/avibactam, colistin, aztreonam,
amikacin, ciprofloxacin, cefepime, tigecycline, minocycline, levofloxacin
and trimethoprim/sulfamethoxazole.24 The CLSI-approved range for cefi-
derocol (E. coli ATCC 25922, 0.06 to 0.5 mg/L; P. aeruginosa ATCC 27853,
0.06 to 0.5 mg/L) was also included.25
Cefiderocol MICs were read as the first drug well in which growth was
significantly reduced (i.e. a button of <1 mm or light/faint turbidity) relative
to the growth observed in the ID-CAMHB growth control well. The method
used for reading MIC endpoints for cefiderocol, described above, was
approved by the CLSI Subcommittee on Antimicrobial Susceptibility Testing
in January 2016.25
CLSI investigational breakpoints for cefiderocol (4mg/L for susceptible;
8 for intermediate; and16 mg/L for resistant)26 were used for assignment
to clinical category.
CLSI interpretive criteria, when available,26 were used to interpret the
MIC values of comparators. Colistin and tigecycline lack CLSI breakpoints
for Enterobacterales and the EUCAST MIC breakpoints for Enterobacterales
were applied for these antimicrobials.27
Results
Antimicrobial activity against MDR-GNB
MIC distributions of cefiderocol for the clinical isolates included in
this study are shown in Figure 1. After applying the CLSI clinical
breakpoints,26 98% of isolates were susceptible, 0.8% intermedi-
ate and 1.2% resistant. Non-susceptible isolates were: three A.
baumannii ST2 OXA-24/40 producers, one E. cloacae ST114 VIM-1
producer and one E. cloacae ST114 co-producing VIM-1 plus OXA-
48 (Figure 1).
Table 2 shows summary data of MIC ranges and MIC50 and
MIC90 values of all antibiotics against the bacterial isolates
tested and their respective resistance percentages. Against
K. pneumoniae, A. baumannii and S. maltophilia, the concentra-
tions of cefiderocol inhibiting 90% of isolates tested (MIC90) were
2, 4 and 0.5 mg/L, respectively. Cefiderocol MICs ranged from
0.03 to 16 mg/L for all isolates, 0.03 to 8 mg/L for
Enterobacterales (0.03 to 4 mg/L for K. pneumoniae) and 0.06 to
16 mg/L for non-fermenting GNB (0.06 to 16 mg/L for A. bauman-
nii, 0.125 to 0.5 for P. aeruginosa and 0.03 to 2 mg/L for S.
maltophilia).
In Enterobacterales, the overall rates of resistance to ceftazi-
dime/avibactam, ceftolozane/tazobactam, meropenem, amikacin,
colistin and tigecycline were 3.2%, 90.4%, 62.4%, 43.2%, 19.2% and
62.4%, respectively. In A. baumannii and P. aeruginosa, the overall
rates of resistance to ceftazidime, cefepime, meropenem, amikacin
and colistin were 90.7%, 82.6%, 96.5%, 47.7% and 15.11%, respect-
ively. All isolates tested were resistant to ciprofloxacin.
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Figure 1. Distribution of cefiderocol MICs for all isolates and clinical category according to investigational CLSI breakpoints. I, intermediate; R, resist-
ant; S, susceptible.
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Table 2. MIC ranges, MIC50s and MIC90s (mg/L) of cefiderocol and comparators and distribution by clinical category (according to CLSI, when avail-
able, and EUCAST when not established) against the MDR GNB tested (n = 231)
Species (no. of isolates) Antimicrobial agent
MIC (mg/L) Clinical category (%)a
MIC range MIC50 MIC90 S I R
K. pneumoniae (n = 121)
cefiderocol 0.03–4 0.5 2 100 0 0
ceftolozane/tazobactam 0.25 to >64 >64 >64 7.4 1.6 90.9
meropenem 0.03 to >64 8 >64 23.9 12.4 63.6
ceftazidime 0.5 to >64 >64 >64 3.3 0.8 95.9
ceftazidime/avibactam 0.03–32 1 4 98.3 NA 1.7
colistinb 0.5–8 0.5 >8 85.9 NA 15.1
aztreonam 0.5 to >32 >32 >32 0 0.8 99.1
amikacin 4 to >64 8 64 60.3 28.1 11.6
ciprofloxacin 1 to >4 >4 >4 0.8 0.8 98.3
cefepime 0.5 to >16 >16 >16 1.7 6.6 91.7
tigecyclineb 0.25 to >4 1 2 85.9 9.1 4.9
E. cloacae (n = 4)
cefiderocol 0.5–8 NC NC 50.0 50.0 0
ceftolozane/tazobactam 0.25 to >64 NC NC 25.0 NA 75.0
meropenem 0.06–8 NC NC 75.0 0 25.0
ceftazidime 8 to >64 NC NC 0 25.0 75.0
ceftazidime/avibactam 0.25 to >64 NC NC 50.0 NA 50.0
colistinb 0.5 NC NC 100 NA 0
aztreonam 8 to >32 NC NC 0 25.0 75.0
amikacin 4–16 NC NC 100 0 0
ciprofloxacin 2 to >4 NC NC 0 25.0 75.0
cefepime 4 to >16 NC NC 0 25.0 75.0
tigecyclineb 0.25–2 NC NC 50.0 50.0 0
A. baumannii (n = 80)
cefiderocol 0.06–16 0.25 4 95 0 5
ceftolozane/tazobactam 4 to >64 16 >64 NA NA NA
meropenem 4 to >64 64 >64 0 3.8 96.2
ceftazidime 4 to >64 64 >64 6.3 2.5 91.2
ceftazidime/avibactam 8 to >64 32 64 NA NA NA
colistin 0.5 to >8 1 4 83.7 NA 16.3
aztreonam 32 to >32 >32 >32 NA NA NA
amikacin 4 to >64 64 >64 37.5 11.3 51.2
ciprofloxacin >4 >4 >4 0 0 100
cefepime 8 to >16 >16 >16 1.2 11.3 87.5
tigecycline 1 to >4 2 4 NA NA NA
P. aeruginosa (n = 6)
cefiderocol 0.125–0.5 NC NC 100 0 0
ceftolozane/tazobactam 2 to >64 NC NC 83.3 0 16.7
meropenem 8–64 NC NC 0 0 100
ceftazidime 16 to >64 NC NC 0 16.7 83.3
ceftazidime/avibactam 4 to >64 NC NC 83.3 NA 16.7
colistin 0.5–1 NC NC 100 NA 0
aztreonam 32 to >32 NC NC 0 0 100
amikacin 4–16 NC NC 100 0 0
ciprofloxacin >4 NC NC 0 0 100
cefepime 16 to >16 NC NC 0 83.3 16.7
tigecycline >4 NC NC NA NA NA
S. maltophilia (n = 20)
cefiderocol 0.03–2 0.25 0.5 100 0 0
Continued
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Antimicrobial activity against MDR Enterobacterales
One hundred and ten of the Enterobacterales included in the
study were carbapenemase producers (108 K. pneumoniae and 2
E. cloacae), one isolate co-produced two carbapenemases
(E. cloacae ST114; VIM-1 plus OXA-48) and 15 produced only ESBLs
(13 K. pneumoniae and 2 E. cloacae) (Table 1).
The MIC ranges and MIC50 and MIC90 values of cefiderocol and
comparators against this group of isolates are shown in Table 3.
Applying CLSI breakpoints for cefiderocol, 100% of isolates, includ-
ing KPC-3 producers, were susceptible to this cephalosporin. All iso-
lates were ciprofloxacin resistant, 90% (46/51) were amikacin
resistant and one (1.9%) isolate (ST512) was resistant to ceftazi-
dime/avibactam; 13 (12 ST512 and 1 ST258) (25.5%) and 3 (one
ST512, one ST258 and one ST147) (5.9%) isolates showed MICs of
4 mg/L for colistin and tigecycline, respectively. Among OXA-48
producers, 43.9% (25/57) were resistant to meropenem, 3.5% (2/
57) to amikacin and 11 (19.3%) and 4 (7.0%) isolates, respectively,
showed colistin and tigecycline MICs of4 mg/L. After cefiderocol,
the second most active agent against carbapenemase-producing
K. pneumoniae was the ceftazidime/avibactam combination (1.8%
of isolates were resistant; 2/108), regardless of the type of carba-
penemase or clone.
All isolates producing only ESBLs, with no carbapenemases,
were CTX-M-15 producers (Table 1). The cefiderocol MIC for all of
this group of isolates was2 mg/L and rates of resistance to cipro-
floxacin and meropenem were 100% and 7%, respectively. No re-
sistance to ceftazidime/avibactam was observed, nor any
differences in activity between different clones.
All E. cloacae isolates belonged to the ST114 clone (Table 1).
Two of the four were CTX-M-15 producers and the other two pro-
duced VIM-1; one of them co-produced VIM-1 and OXA-48. MIC
range, MIC50 and MIC90 values are shown in Table 2. According to
CLSI breakpoints, two isolates were intermediate to cefiderocol
and both were VIM-1 producers. The other two produced only CTX-
M-15 and displayed cefiderocol MICs of0.5 mg/L.
Activity of cefiderocol against non-fermenting GNB
The distribution of non-fermenting GNB included in the study is
shown in Table 1.
The MIC ranges and MIC50 and MIC90 values of cefiderocol and
comparators for oxacillinase-producing A. baumannii, grouped by
clone and type of carbapenemase, are shown in Table 4. Three out
of 80 isolates presented MIC values of 16 mg/L, all of which were
ST2/OXA-24/40 producers and presented different pulsotypes.
Applying CLSI breakpoints, the global resistance rate was 3.8% for
all A. baumannii and 12.0% for the ST2/OXA-24/40 group.
Colistin resistance was observed in 13 isolates (16.3%: 5 ST2/
OXA-23 and 8 ST2/OXA-58) and all were susceptible to cefiderocol
(MIC range: 0.06–0.5 mg/L). Forty-one (51.3%) isolates were resist-
ant to amikacin (14 ST2/OXA-23, 20 ST2/OXA-24/40, 6 ST2/OXA-58
and 1 ST745/OXA-23). The MIC50 and MIC90 values of cefiderocol
for isolates resistant or intermediate to amikacin were one dilution
higher than for those that were amikacin susceptible (MIC50: 0.5
and 0.25 mg/L, respectively; MIC90: 4 and 2 mg/L, respectively).
The two isolates with cefiderocol MIC >4 mg/L were also amikacin
resistant.
Five of the carbapenem-resistant P. aeruginosa isolates eval-
uated were ST175 non-carbapenemase producers and one was an
ST253/IMP-16 producer (Table 1). MIC ranges and MIC50 and MIC90
values of cefiderocol and comparators for these isolates are shown
in Table 2. The MICs of cefiderocol ranged from 0.125 to 0.5 mg/L.
The carbapenemase isolate displayed the highest MIC values for
this species. All isolates were susceptible to cefiderocol, including
one IMP producer that was resistant to ceftolozane/tazobactam
and ceftazidime/avibactam.
Finally, 20 S. maltophilia isolates were included (Table 1) and 15
different MLST profiles were identified among these isolates (data
not shown). MIC ranges and MIC50 and MIC90 values of cefiderocol
and comparators for these isolates, as well as resistance rates, are
shown in Table 2. All of these isolates were susceptible to cefidero-
col (MIC 2mg/L). Resistance rates to ceftazidime, levofloxacin
and trimethoprim/sulfamethoxazole were 85%, 5% and 5%, re-
spectively; three (15%) isolates were intermediate to levofloxacin.
Table 2. Continued
Species (no. of isolates) Antimicrobial agent
MIC (mg/L) Clinical category (%)a
MIC range MIC50 MIC90 S I R
ceftolozane/tazobactam 0.5 to >64 32 >64 NA NA NA
meropenem 16 to >64 >64 >64 NA NA NA
ceftazidime 4 to >64 >64 >64 15.0 0 85.0
ceftazidime/avibactam 2 to >64 32 >64 NA NA NA
colistin 0.5 to >8 >8 >8 NA NA NA
amikacin 4 to >64 >64 >64 NA NA NA
tigecycline 0.25–4 0.5 2 NA NA NA
levofloxacin 1–8 1 4 80.0 15.0 5.0
minocycline 2–4 2 4 100 0 0
trimethoprim/sulfamethoxazole 0.25 to >16 0.25 2 95.0 NA 5.0
NA, not applicable; NC, not calculated because the number of test strains was <10; I, intermediate; R, resistant; S, susceptible.
aCLSI breakpoints.
bEUCAST breakpoints.
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Table 3. MIC ranges, MIC50s and MIC90s (mg/L) of cefiderocol and comparators for 107 carbapenemase-producing K. pneumoniae, grouped by clone
and type of carbapenemase produced
Isolates Antimicrobial agent MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
ST11/OXA-48!CTX-M-15 (n = 25)
cefiderocol 0.03–4 0.25 2
ceftolozane/tazobactam 16 to >64 >64 >64
meropenem 0.25–64 2 8
ceftazidime 8 to >64 64 >64
ceftazidime/avibactam 0.5–2 1 2
colistin 0.5 to >8 0.5 4
aztreonam 32 to >32 >32 >32
amikacin 4–64 8 16
ciprofloxacin >4 >4 >4
cefepime 8 to >16 >16 >16
tigecycline 0.5–2 1 2
ST15/OXA-48!CTX-M-15 (n = 25)
cefiderocol 0.03–4 0.25 4
ceftolozane/tazobactam 0.5 to >64 64 >64
meropenem 1–64 2 64
ceftazidime 0.5 to >64 64 >64
ceftazidime/avibactam 0.03–4 0.5 1
colistin 0.5 to >8 0.5 2
aztreonam 0.5 to >32 >32 >32
amikacin 4–8 4 4
ciprofloxacin 1 to >4 >4 >4
cefepime 0.5 to >16 >16 >16
tigecycline 0.25–2 0.5 2
ST512/KPC-3 (n = 25)
cefiderocol 0.25–4 2 4
ceftolozane/tazobactam >64 >64 >64
meropenem >64 >64 >64
ceftazidime >64 >64 >64
ceftazidime/avibactam 2–16 4 8
colistin 0.5 to >8 2 >8
aztreonam >32 >32 >32
amikacin 32 to >64 32 64
ciprofloxacin >4 >4 >4
cefepime >16 >16 >16
tigecycline 1–4 1 2
ST258/KPC-3 (n = 25)
cefiderocol 0.06–4 2 2
ceftolozane/tazobactam 64 to >64 >64 >64
meropenem 8 to >64 16 64
ceftazidime >64 >64 >64
ceftazidime/avibactam 2–4 2 2
colistin 0.5 to >8 0.5 1
aztreonam >32 >32 >32
amikacin 4–32 32 32
ciprofloxacin >4 >4 >4
cefepime 16 to >16 >16 >16
tigecycline 0.5–4 0.5 1
ST147/OXA-48 (n = 3)
cefiderocol 0.06–0.5 0.25 0.5
ceftolozane/tazobactam 8 to >64 64 >64
meropenem 0.5 to >64 1 >64
Continued
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Apart from cefiderocol, minocycline was the most active agent,
with 100% of isolates being susceptible.
Discussion
To our knowledge, this is the first study to evaluate the in vitro ac-
tivity of cefiderocol against a well-characterized collection of HR
isolates of MDR-GNB. This collection includes the most representa-
tive MDR bacteria causing healthcare-associated infections in
southern Spain (Andalusia has a population of more than 8 million
people) and very similar to those that cause infections in neigh-
bouring countries.
The results obtained from the current study showed that the
in vitro activity of cefiderocol was superior to that of comparators
against recent clinical HR clone isolates of ESBL- and/or
carbapenemase-producing Enterobacterales, carbapenem-non-
susceptible P. aeruginosa, oxacillinase-producing A. baumannii and
MDR S. maltophilia.
Cefiderocol showed potent antimicrobial activity, with MIC90
values of 4 mg/L for all groups of organisms evaluated. The
MIC90 of cefiderocol was lower for Enterobacterales than for non-
fermenting GNB, except for S. maltophilia where the MIC90 was
0.5 mg/L.
Against K. pneumoniae, cefiderocol exhibited MIC90 values that
were 2 to 16 times lower than those of comparator agents.
Against A. baumannii, cefiderocol (MIC90, 4 mg/L) was up to four
times more potent than the comparator agents tested, with the
exception of colistin and tigecycline, which also had MIC90 values
of 4 mg/L. S. maltophilia was highly susceptible to cefiderocol
(MIC90 0.5 mg/L) and cefiderocol was at least as active as compa-
rators, including trimethoprim/sulfamethoxazole (MIC90 2 mg/L).
These data demonstrate that cefiderocol has markedly high
activity against the isolates of K. pneumoniae, A. baumannii,
P. aeruginosa and S. maltophilia that were tested, including
carbapenemase-producing strains.
Our results are consistent with previous studies.8,28 Ito-
Horiyama et al.8 evaluated the activity of cefiderocol, meropenem,
levofloxacin, cefepime, ceftazidime and piperacillin/tazobactam
against a collection of carbapenem-resistant non-fermenting
GNB, including A. baumannii, P. aeruginosa and S. maltophilia. In
their study, cefiderocol demonstrated significantly lower MIC90
values than all comparators for all groups of bacteria. Kohira et al.28
analysed the activity of cefiderocol against Enterobacterales. MIC90
values of cefiderocol against K. pneumoniae and E. cloacae were
0.125 and 1 mg/L, respectively, and comparators had higher values
in all cases. In both studies, medium containing apo-transferrine
was used instead of ID-CAMHB.
In our study, all carbapenemase-producing K. pneumoniae
were susceptible to cefiderocol, whereas a previous study found
12 isolates of carbapenem-non-susceptible K. pneumoniae with
MIC values of >4 mg/L.29 The latter study did not specify which
underlying mechanism of action was present in their isolates that
were not susceptible to carbapenems. As far as we know, few KPC-
3-producing K. pneumoniae have been evaluated. Other studies
have analysed cefiderocol activity against KPC-producing K. pneu-
moniae isolates,8,12,28 although the proportion of KPC-3 is un-
known, whereas in our study, all isolates belonging to the HR
ST512 and ST258 clones were KPC-3 producers. Dobias et al.12
demonstrated that cefiderocol MICs for KPC-type carbapene-
mase-producing K. pneumoniae ranged between 0.03 and 64 mg/
L. Nevertheless, cefiderocol MICs of 4 mg/L were obtained for all
KPC-type producers analysed by other authors, as was the case in
our study.
Table 3. Continued
Isolates Antimicrobial agent MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
ceftazidime 32 to >64 64 >64
ceftazidime/avibactam 0.125–32 2 32
colistin 0.5 0.5 0.5
aztreonam 32 to >32 >32 >32
amikacin 4–64 4 64
ciprofloxacin >4 >4 >4
cefepime 8 to >16 >16 >16
tigecycline 0.25–4 0.5 4
ST392/OXA-48!CTX-M-15 (n = 4)
cefiderocol 0.06–1 0.25 1
ceftolozane/tazobactam 8–64 32 64
meropenem 1–16 8 16
ceftazidime 16–64 32 64
ceftazidime/avibactam 0.25–0.5 0.25 0.5
colistin 0.5–1 0.5 1
aztreonam 32 to >32 >32 >32
amikacin 4 4 4
ciprofloxacin >4 >4 >4
cefepime 4 to >16 >16 >16
tigecycline 1 to >4 >4 >4
I, intermediate; R, resistant; S, susceptible.
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Several studies have analysed the activity of cefiderocol against
OXA-48-type-producing K. pneumoniae isolates. According to
previous data, the cefiderocol MIC range for 88 OXA-48-like-
producing K. pneumoniae was 0.03–64 mg/L, with an MIC90 of
1 mg/L, and just one resistant isolate.12 Kohira et al.28 reported
that 3 out of 81 carbapenemase-producing K. pneumoniae were
OXA-48 producers, all with MICs of 0.5 mg/L; the medium used
for testing cefiderocol MIC in this study was supplemented with
apo-transferrine, while in our previously cited study the medium
used was ID-CAMHB. In our study, all OXA-48-producing isolates
demonstrated cefiderocol MICs of4 mg/L. In addition, the results
of our study showed that isolates co-producing OXA-48 and CTX-
M-15 had MICs of 4 mg/L, whereas isolates that only produced
OXA-48 displayed MICs 1 mg/L, independently of the clone. A
possible explanation for this finding is that the combination of b-
lactamases could decrease cefiderocol activity against these
isolates. Nevertheless, they continued to demonstrate MICs in the
susceptible range.
Two isolates of E. cloacae ST114/VIM-1 (one of them co-
producing OXA-48) showed MICs of 8 mg/L. Previously,
Enterobacter spp. demonstrated higher MIC90 (8 mg/L) values
than other genera/species of Enterobacterales.29 Hackel et al.29
showed that cefiderocol inhibited 97.8% (222/227) of
carbapenem-non-susceptible Enterobacterales, 15 of which were
E. cloacae. VIM-1-producing E. cloacae strains have previously
been reported as resistant to cefiderocol.12,28 However, cefiderocol
showed 100% susceptibility in 53 VIM producers from the multi-
national SIDERO-WT-2014 study, including 7 E. cloacae.30
Three of our A. baumannii isolates (12.0%) were resistant to
cefiderocol (16 mg/L), all of them belonging to the HR ST2 clone
and producers of OXA-24/40. Previous studies have reported MICs
of >8 mg/L for A. baumannii,12,29,31 although other studies have
Table 4. MIC ranges, MIC50s and MIC90s (mg/L) of cefiderocol and commercial comparators for 80 oxacillinase-producing A. baumannii, grouped by
clone and type of carbapenemase produced
Species Antimicrobial agent
MIC (mg/L) Clinical category (%)
MIC range MIC50 MIC90 S I R
ST2/OXA-23 (n = 25)
cefiderocol 0.06–1 0.25 0.5 100 0 0
meropenem 16 to >64 64 64 0 0 100
ceftazidime 4 to >64 64 >64 20 8 72
colistin 0.5 to >8 1 >8 84 NA 16
amikacin 4 to >64 >64 >64 44 0 56
ciprofloxacin >4 >4 >4 0 0 100
cefepime >16 >16 >16 0 0 100
ST2/OXA-24/40 (n = 25)
cefiderocol 0.5–16 2 16 88 0 12
meropenem >64 >64 >64 0 0 100
ceftazidime 32 to >64 >64 >64 0 0 100
colistin 0.5–1 0.5 2 100 NA 0
amikacin 4 to >64 64 >64 16 4 80
ciprofloxacin >4 >4 >4 0 0 100
cefepime >16 >16 >16 0 0 100
ST2/OXA-58 (n = 25)
cefiderocol 0.06–0.5 0.125 0.5 100 0 0
meropenem 4–64 8 64 0 12 88
ceftazidime 32 to >64 >64 >64 0 0 100
colistin 0.5 to >8 1 8 64 NA 36
amikacin 4 to >64 32 >64 44 32 24
ciprofloxacin >4 >4 >4 0 0 100
cefepime 8 to >16 >16 >16 4 28 68
ST745/OXA-58 (n = 5)
cefiderocol 0.06–0.25 NC NC 100 0 0
meropenem 8–16 NC NC 0 0 100
ceftazidime >64 NC NC 0 0 100
colistin 0.5–2 NC NC 100 NA 0
amikacin 4 to >64 NC NC 80 0 20
ciprofloxacin >4 NC NC 0 0 100
cefepime 16 to >16 NC NC 0 40 60
NA, not applicable; NC, not calculated because the number of test strains was <10; I, intermediate; R, resistant; S, susceptible.
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reported all A. baumannii isolates as susceptible, with MIC90 values
of 0.5 mg/L.11 Ito et al.31 found five strains showing cefiderocol
MICs of 8 mg/L and two strains with MICs of 32 mg/L. Dobias
et al.12 reported seven OXA-23-producing A. baumannii, represent-
ing 30% of all isolates with cefiderocol MICs >8 mg/L. In that study,
the number of isolates that produced OXA-23 and OXA-58, re-
spectively and the clone to which they belonged was not specified.
None of the isolates produced OXA-24/40. With the available data,
it is not possible to establish whether one type of oxacillinase has
more activity than another against cefiderocol. Our results suggest
that the lower activity is not related to the clone, since most iso-
lates in our collection belonged to the same clone. Even so, all re-
sistant isolates produced a single type of oxacillinase.
With respect to P. aeruginosa, the number of isolates of HR
clones included in the present study was small and only one pro-
duced a carbapenemase (VIM-1), although all were resistant to
carbapenems. All data available show that cefiderocol has excel-
lent activity against MDR P. aeruginosa.8,9,11,12 The numbers of
cefiderocol-resistant P. aeruginosa isolates reported are small:
Hackel et al.29 described two isolates of MDR P. aeruginosa with
cefiderocol MICs of >8 mg/L and Ito et al.9 found two isolates of
VIM-type-producing P. aeruginosa with cefiderocol MICs of 8 mg/L.
In our study, cefiderocol displayed more potent in vitro activity
against S. maltophilia compared with previously published data, in
which the MIC values obtained for isolates of this species were
4 mg/L.32 The isolates in our collection showed cefiderocol MICs
of2 mg/L.
Our study has some strengths and limitations. The main
strength of this study is that it is the first to include a well-
characterized collection of MDR-GNB isolates belonging to HR
clones. Second, the collection reflects the current local epidemi-
ology of a large and specific geographical area. The first limitation
is the low number of isolates of enterobacteria other than
K. pneumoniae included, as well as of P. aeruginosa isolates. The
second limitation is the low number of MBL-producing isolates.
Most of the isolates reported as non-susceptible to cefiderocol in
the literature correspond to isolates producing MBLs, so it would
be necessary to conduct a larger-scale study focusing on isolates
producing these enzymes.
In conclusion, cefiderocol demonstrated excellent activity
against MDR-GNB isolates, including carbapenemase-
producing isolates, regardless of the type of carbapenemase or
clone. Isolates of A. baumannii ST2/OXA-24/40 and E. cloacae
ST114/VIM-1 showed resistance to this antimicrobial, so it
will be necessary to conduct further studies to establish the
spectrum of cefiderocol activity. This new antimicrobial
has great potential for the treatment of infections caused by
MDR-GNB.
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